Adjuvant Nivolumab Plus Ipilimumab Vs Placebo for Patients with Localized Renal Cell Carcinoma at High Risk of Relapse after Nephrectomy: Subgroup Analyses from the Phase 3 CheckMate 914 (part A) Trial.
JOURNAL OF CLINICAL ONCOLOGY（2023）
Key words
Neoadjuvant Therapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined